source
- Skyhawk reports functional gains in Huntington's disease trial of RNA-splicing pillSkyhawk Therapeutics, a Boston biotech backed by Fidelity, released final data from a small mid-stage trial of its once-daily RNA-splicing pill for Huntington's disease. After 15 months, patients…
- Experts urge more representative enrollment in clinical trialsA panel of regulators and industry leaders gathered to discuss how clinical trials can better reflect the diversity of patient populations. The discussion included officials from the U.S. Food and…